OBJECTIVES: The impact of rheumatoid arthritis (RA) on patients’ work ability is well established. However, there is growing recognition of the impact on patients’ ability to perform household duties and social activities. This evaluates the impact of certolizumab pegol (CZP) plus methotrexate (MTX) on productivity within and outside the home in patients with active RA. METHODS: In RAPID1 and 2, productivity was assessed 4-weekly from baseline using the novel validated Work Productivity Survey (WPS-RA) that measures productivity limitations due to RA on work outside the home, household work and social activities. Mean changes from baseline in missed days of household work, days with reduced household productivity, missed days of family/social/leisure activities, self-reported work absenteeism and presenteeism (work days with productivity reduced by ≥50%) and RA impact on productivity a 0-10 scale (10=complete interference) were compared between treatment arms using non-parametric bootstrap-t methodology. RESULTS: A total 982 and 619 patients were randomized into RAPID1, and 2, respectively. Baseline employment rates were 41.6% and 39.8%, respectively. The other patients included homemakers, retirees, those unable to work due to RA, and those unemployed for other reasons. Within each trial, treatment groups were comparable at baseline for productivity within and outside the home. In both trials, improvements in productivity within and outside the home were observed in the CZP arms as early as Week 4, and maintained until study end (RAPID1: 12 months, RAPID2: 6 months). In RAPID1, patients on CZP 200mg+MTX reported significant decreases at Week 24 in days missed of household work (mean change -4.67 vs -1.54 days/month for MTX alone) and days with reduced productivity (mean change -5.68 vs -2.85 days/month for MTX alone). Similar improvements were reported with CZP 400mg+MTX and in RAPID2. Improvements in work productivity and daily activities were reported. CONCLUSIONS: CZP improves productivity within and outside the home in RA patients.